Concepts (106)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 6 | 2024 | 447 | 1.150 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 22 | 0.880 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 3 | 0.760 |
Why?
|
| Cancer Survivors | 2 | 2024 | 38 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 12 | 0.320 |
Why?
|
| Lymphoma, B-Cell | 1 | 2009 | 18 | 0.320 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 12 | 0.320 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2009 | 3 | 0.320 |
Why?
|
| Etoposide | 1 | 2009 | 19 | 0.310 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 659 | 0.310 |
Why?
|
| Heart Diseases | 1 | 2009 | 69 | 0.300 |
Why?
|
| Piperazines | 2 | 2022 | 45 | 0.270 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2006 | 15 | 0.260 |
Why?
|
| Interferons | 1 | 2006 | 68 | 0.260 |
Why?
|
| Cardiomyopathies | 1 | 2006 | 33 | 0.250 |
Why?
|
| E-Selectin | 2 | 2016 | 27 | 0.250 |
Why?
|
| Libido | 1 | 2024 | 1 | 0.230 |
Why?
|
| Bupropion | 1 | 2024 | 2 | 0.230 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 61 | 0.220 |
Why?
|
| Female | 10 | 2024 | 14658 | 0.200 |
Why?
|
| Humans | 11 | 2024 | 27175 | 0.200 |
Why?
|
| Ki-67 Antigen | 1 | 2022 | 23 | 0.200 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 32 | 0.190 |
Why?
|
| Salivary Ducts | 1 | 2021 | 3 | 0.190 |
Why?
|
| Pyridines | 1 | 2022 | 102 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 375 | 0.150 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2017 | 9 | 0.140 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2017 | 9 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 24 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 79 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 156 | 0.120 |
Why?
|
| Aptamers, Nucleotide | 1 | 2015 | 13 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 312 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 287 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 268 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 305 | 0.110 |
Why?
|
| Aged | 4 | 2024 | 5232 | 0.110 |
Why?
|
| Middle Aged | 4 | 2024 | 6918 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 990 | 0.090 |
Why?
|
| Aging | 1 | 2018 | 960 | 0.090 |
Why?
|
| Adult | 3 | 2024 | 7510 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 17 | 0.080 |
Why?
|
| Trisomy | 1 | 2009 | 18 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 41 | 0.080 |
Why?
|
| Rituximab | 1 | 2009 | 60 | 0.080 |
Why?
|
| Eosinophils | 1 | 2009 | 6 | 0.080 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 12 | 0.080 |
Why?
|
| Benzamides | 1 | 2009 | 33 | 0.080 |
Why?
|
| Survival Rate | 2 | 2022 | 412 | 0.080 |
Why?
|
| Male | 4 | 2017 | 13034 | 0.080 |
Why?
|
| Recurrence | 1 | 2009 | 317 | 0.070 |
Why?
|
| Meningioma | 1 | 2009 | 79 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 455 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2009 | 121 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 318 | 0.070 |
Why?
|
| Chest Pain | 1 | 2006 | 25 | 0.070 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 16 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2024 | 6 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2024 | 405 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 15 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2022 | 23 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2009 | 2289 | 0.050 |
Why?
|
| Phthalazines | 1 | 2022 | 22 | 0.050 |
Why?
|
| Pregnancy | 1 | 2006 | 1153 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 217 | 0.050 |
Why?
|
| Oxyhemoglobins | 1 | 2018 | 10 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 467 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 92 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 104 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 179 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 119 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 244 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 190 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 398 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 30 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 133 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 291 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 310 | 0.030 |
Why?
|
| Complement C5a | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 264 | 0.030 |
Why?
|
| Complement C3a | 1 | 2015 | 6 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mice, Inbred ICR | 1 | 2015 | 26 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 65 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 250 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 23 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 762 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 81 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 218 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 353 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 458 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 591 | 0.030 |
Why?
|
| Kidney | 1 | 2015 | 275 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2016 | 793 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 1573 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 1943 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 774 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2015 | 597 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 440 | 0.030 |
Why?
|
| Apoptosis | 1 | 2016 | 738 | 0.030 |
Why?
|
| Liver | 1 | 2015 | 424 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 10082 | 0.020 |
Why?
|
| Biomarkers | 1 | 2015 | 736 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2017 | 2464 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 4472 | 0.020 |
Why?
|